ArticleFrontiers in aging neuroscience2026
Dopamine 2 receptor ablation from cholinergic neurons attenuates L-DOPA induced dyskinesias.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
3 authors.
Funding
Abstract
Introduction: L-DOPA-induced dyskinesia (LID) formation requires prominent dopamine oscillations over hours, across years of treatment. Striatal cholinergic interneurons (CIN) have been implicated in both the facilitation and attenuation of LID, but how CIN sense and respond to striatal dopamine levels in this context remains incompletely understood. CIN express both the inhibitory, Gα Methods: We generated mice with conditional ablation of D2 from choline acetyltransferase-expressing cells (D2 Results: D2 Discussion: Together, these findings indicate that D2 signaling in CIN promotes LID formation and suggest that CIN D2 is a potential molecular target for mitigating dyskinesias while preserving the therapeutic efficacy of L-DOPA. These results are discussed in the context of recently refined models of how CIN may contribute to aberrant plasticity in the basal ganglia of the Parkinsonian mouse brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.